Polymyalgia rheumatica

Nothnagl T, Leeb BF. Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica. Drugs Aging. 2006;23:391-402. Abstract

Buttgereit F, Dejaco C, Matteson EL, et al. Polymyalgia rheumatica and giant cell arteritis: A systematic review. JAMA. 2016 Jun 14;315(22):2442-58. Abstract

Dejaco C, Singh YP, Perel P, et al; European League Against Rheumatism; American College of Rheumatology. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2015;67:2569-2580.Full text  Abstract

1. Ceccato F, Roverano SG, Papasidero S, et al. Peripheral musculoskeletal manifestations in polymyalgia rheumatica. J Clin Rheumatol. 2006;12:167-171. Abstract

2. Raheel S, Shbeeb I, Crowson CS, et al. Epidemiology of polymyalgia rheumatica 2000-2014 and examination of incidence and survival trends over 45 years: A population-based study. Arthritis Care Res (Hoboken). 2017 Aug;69(8):1282-5.Full text  Abstract

3. Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol. 2000;18:S9-S11. Abstract

4. Nothnagl T, Leeb BF. Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica. Drugs Aging. 2006;23:391-402. Abstract

5. Soubrier M, Dubost JJ, Ristori JM. Polymyalgia rheumatica: diagnosis and treatment. Joint Bone Spine. 2006;73:599-605. Abstract

6. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454-1461. Abstract

7. Partington R, Muller S, Mallen CD, et al. Mortality among patients with polymyalgia rheumatica: A retrospective cohort study. Arthritis Care Res (Hoboken). 2020 Aug 2 [Epub ahead of print].Full text  Abstract

8. Salvarani C, Gabriel SE, O'Fallon WM, et al. Epidemiology of polymyalgia rheumatica in Olmstead County, Minnesota, 1970-1991. Arthritis Rheum. 1995;38:369-373. Abstract

9. Unwin B, Williams CM, Gilliland W. Polymyalgia rheumatica and giant cell arteritis. Am Fam Physician. 2006;74:1547-1554.Full text  Abstract

10. Doran MF, Crowson CS, O'Fallon WM, et al. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol. 2002;29:1694-1697. Abstract

11. Buttgereit F, Dejaco C, Matteson EL, et al. Polymyalgia rheumatica and giant cell arteritis: A systematic review. JAMA. 2016 Jun 14;315(22):2442-58. Abstract

12. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003;139:505-515. Abstract

13. Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484-491. Abstract

14. Samson M, Audia S, Fraszczak J, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012;64:3788-3798.Full text  Abstract

15. van der Geest KS, Abdulahad WH, Chalan P, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol. 2014;66:1927-1938. Abstract

16. Kreiner F, Galbo H. Elevated muscle interstitial levels of pain-inducing substances in symptomatic muscles in patients with polymyalgia rheumatica. Pain. 2011;152:1127–1132. Abstract

17. Dejaco C, Duftner C, Wipfler E, et al. 18F-Fluorodeoxyglucose positron emission tomography in polymyalgia rheumatica: novel insight into complex pathogenesis but questionable use in predicting relapses. Rheumatology (Oxford). 2007;46:559-560.Full text  Abstract

18. Hutchings A, Hollywood J, Lamping DL, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum. 2007;57:803-809. Abstract

19. Marsman DE, den Broeder N, Boers N, et al. Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica? Clin Exp Rheumatol. 2021 Jan-Feb;39(1):32-7. Abstract

20. Ceccato F, Roverano S, Barrionuevo A, et al. The role of anticyclic citrullinated peptide antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Clin Rheumatol. 2006 Nov;25(6):854-7. Abstract

21. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med. 2018;56(12):2015-38. Abstract

22. Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol. 2005;23:462-468. Abstract

23. Camellino D, Cimmino MA. Imaging of polymyalgia rheumatica: indications on its pathogenesis, diagnosis and prognosis. Rheumatology 2012;51:77-86. Abstract

24. Kim K, Kim SJ. Diagnostic performance of F-18 fluorodeoxyglucose PET/computed tomography for diagnosis of polymyalgia rheumatica: a meta-analysis. Nucl Med Commun. 2020 Dec;41(12):1313-21. Abstract

25. van der Geest KSM, Treglia G, Glaudemans AWJM, et al. Diagnostic value of [18F]FDG-PET/CT in polymyalgia rheumatica: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1876-89.Full text  Abstract

26. Salvarani C, Boiardi L, Mantovani V, et al. HLA-DRB1, DQA1, and DQB1 alleles associated with giant cell arteritis in northern Italy. J Rheumatol. 1999;26:2395-2399. Abstract

27. Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis. 1981;40:1-5. Abstract

28. Helfgott SM, Kieval RI. Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate. Arthritis Rheum. 1996;39:304-307. Abstract

29. Salvarani C, Cantini F, Niccoli L, et al. Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 2005;53:33-38. Abstract

30. Weyand CM, Fulbright JW, Evans JM, et al. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med. 1999;159:577-584.Full text  Abstract

31. Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum. 2000;30:17-24. Abstract

32. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454. Abstract

33. Schreiber S, Buyse M. The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica. Clin Rheumatol. 1995;14:315-318. Abstract

34. Carey K, Saboury B, Basu S, et al. Evolving role of FDG PET imaging in assessing joint disorders: a systematic review. Eur J Nucl Med Mol Imaging. 2011;38:1939-1855. Abstract

35. Pease CT, Haugeberg G, Morgan AW, et al. Diagnosing late onset rheumatoid arthritis, polymyalgia rheumatica, and temporal arteritis in patients presenting with polymyalgic symptoms: a prospective longterm evaluation. J Rheumatol. 2005;32:1043-1046. Abstract

36. Lopez-Hoyos M, Ruiz de Alegria C, Blanco R, et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford). 2004;43:655-657.Full text  Abstract

37. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum. 1990 Feb;33(2):160-72. Abstract

38. Olive A, del Blanco J, Pons M, et al. The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalan Group for the Study of RS3PE. J Rheumatol. 1997;24:333-336. Abstract

39. Cantini F, Salvarani C, Olivieri I, et al. Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis. 1999;58:230-236. Abstract

40. Arima K, Origuchi T, Tamai M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64:1653-1655. Abstract

41. Bird HA, Esselinckx W, Dixon AS, et al. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979;38:434-439. Abstract

42. Chuang TY, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982;97:672-680. Abstract

43. Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum. 1984;13:322-328. Abstract

44. Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum. 2012;64:943-954.Full text  Abstract

45. Dejaco C, Singh YP, Perel P, et al; European League Against Rheumatism; American College of Rheumatology. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2015;67:2569-2580.Full text  Abstract

46. Li C, Dasgupta B. Corticosteroids in polymyalgia rheumatica: a review of different treatment schedules. Clin Exp Rheumatol. 2000;18:S56-S57. Abstract

47. American College of Rheumatology. 2022 Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Oct 2023 [internet publication].Full text

48. Dejaco C, Singh YP, Perel P, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis. 2015;74:1808-1817.Full text  Abstract

49. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762-784. Abstract

50. Dejaco C, Duftner C, Cimmino MA, Dasgupta B, Salvarani C, Crowson CS, Maradit-Kremers H, Hutchings A, Matteson EL, Schirmer M; International Work Group for PMR and GCA. Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Ann Rheum Dis. 2011;70:447–453.Full text  Abstract

51. Lally L, Forbess L, Hatzis C, et al. Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol. 2016 Oct;68(10):2550-4.Full text  Abstract

52. Devauchelle-Pensec V, Berthelot JM, Cornec D, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016 Aug;75(8):1506-10.Full text  Abstract

53. Mori S, Koga Y. Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy. Clin Rheumatol. 2016;35:1367-1375.Full text  Abstract

54. Al Rashidi A, Hegazi MO, Mohammad SA, et al. Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol. 2013;19:400-401. Abstract

55. Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review. Semin Arthritis Rheum. 2020 Jun;50(3):521-5. Abstract

56. Medicines and Healthcare products Regulatory Agency. Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation. Jul 2019 [internet publication].Full text

57. Adizie T, Christidis D, Dharmapaliah C, et al. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012;66:906-909. Abstract

58. Brawer AE. Polymyalgia rheumatica: observations of disease evolution without corticosteroid treatment. Open Access Rheumatol. 2016;8:45-9.Full text  Abstract

59. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2023 Mar;75(3):449-464.Full text  Abstract

60. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261-271. Abstract

61. Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica. Best Pract Res Clin Rheumatol. 2004;18:705-722. Abstract

62. Gabriel SE, Sunku J, Salvarani C, et al. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40:1873-1878. Abstract

63. Hancock AT, Mallen CD, Muller S, et al. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ. 2014;186:E495-E501.Full text  Abstract

64. Jiménez-Palop M, Naredo E, Humbrado L, et al. Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica. Ann Rheum Dis. 2010;69:879-882. Abstract